204 related articles for article (PubMed ID: 24565518)
1. Modulation of matrix elasticity with PEG hydrogels to study melanoma drug responsiveness.
Tokuda EY; Leight JL; Anseth KS
Biomaterials; 2014 May; 35(14):4310-8. PubMed ID: 24565518
[TBL] [Abstract][Full Text] [Related]
2. PEG-peptide hydrogels reveal differential effects of matrix microenvironmental cues on melanoma drug sensitivity.
Tokuda EY; Jones CE; Anseth KS
Integr Biol (Camb); 2017 Jan; 9(1):76-87. PubMed ID: 28001152
[TBL] [Abstract][Full Text] [Related]
3. Combination therapy with vemurafenib (PLX4032/RG7204) and metformin in melanoma cell lines with distinct driver mutations.
Niehr F; von Euw E; Attar N; Guo D; Matsunaga D; Sazegar H; Ng C; Glaspy JA; Recio JA; Lo RS; Mischel PS; Comin-Anduix B; Ribas A
J Transl Med; 2011 May; 9():76. PubMed ID: 21609436
[TBL] [Abstract][Full Text] [Related]
4. Concurrent MEK and autophagy inhibition is required to restore cell death associated danger-signalling in Vemurafenib-resistant melanoma cells.
Martin S; Dudek-Perić AM; Maes H; Garg AD; Gabrysiak M; Demirsoy S; Swinnen JV; Agostinis P
Biochem Pharmacol; 2015 Feb; 93(3):290-304. PubMed ID: 25529535
[TBL] [Abstract][Full Text] [Related]
5. Multifunctional bioscaffolds for 3D culture of melanoma cells reveal increased MMP activity and migration with BRAF kinase inhibition.
Leight JL; Tokuda EY; Jones CE; Lin AJ; Anseth KS
Proc Natl Acad Sci U S A; 2015 Apr; 112(17):5366-71. PubMed ID: 25870264
[TBL] [Abstract][Full Text] [Related]
6. Impact of Collagen Triple Helix Structure on Melanoma Cell Invadopodia Formation and Matrix Degradation upon BRAF Inhibitor Treatment.
Shin DS; Schroeder ME; Anseth KS
Adv Healthc Mater; 2022 Apr; 11(7):e2101592. PubMed ID: 34783464
[TBL] [Abstract][Full Text] [Related]
7. Bioengineered 3D brain tumor model to elucidate the effects of matrix stiffness on glioblastoma cell behavior using PEG-based hydrogels.
Wang C; Tong X; Yang F
Mol Pharm; 2014 Jul; 11(7):2115-25. PubMed ID: 24712441
[TBL] [Abstract][Full Text] [Related]
8. A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib.
Graziani G; Artuso S; De Luca A; Muzi A; Rotili D; Scimeca M; Atzori MG; Ceci C; Mai A; Leonetti C; Levati L; Bonanno E; Tentori L; Caccuri AM
Biochem Pharmacol; 2015 May; 95(1):16-27. PubMed ID: 25795251
[TBL] [Abstract][Full Text] [Related]
9. Pharmacodynamic characterization of the efficacy signals due to selective BRAF inhibition with PLX4032 in malignant melanoma.
Tap WD; Gong KW; Dering J; Tseng Y; Ginther C; Pauletti G; Glaspy JA; Essner R; Bollag G; Hirth P; Zhang C; Slamon DJ
Neoplasia; 2010 Aug; 12(8):637-49. PubMed ID: 20689758
[TBL] [Abstract][Full Text] [Related]
10. PLX4032, a potent inhibitor of the B-Raf V600E oncogene, selectively inhibits V600E-positive melanomas.
Lee JT; Li L; Brafford PA; van den Eijnden M; Halloran MB; Sproesser K; Haass NK; Smalley KS; Tsai J; Bollag G; Herlyn M
Pigment Cell Melanoma Res; 2010 Dec; 23(6):820-7. PubMed ID: 20973932
[TBL] [Abstract][Full Text] [Related]
11. Untangling the response of bone tumor cells and bone forming cells to matrix stiffness and adhesion ligand density by means of hydrogels.
Jiang T; Zhao J; Yu S; Mao Z; Gao C; Zhu Y; Mao C; Zheng L
Biomaterials; 2019 Jan; 188():130-143. PubMed ID: 30343256
[TBL] [Abstract][Full Text] [Related]
12. Differential inhibition of ex-vivo tumor kinase activity by vemurafenib in BRAF(V600E) and BRAF wild-type metastatic malignant melanoma.
Tahiri A; Røe K; Ree AH; de Wijn R; Risberg K; Busch C; Lønning PE; Kristensen V; Geisler J
PLoS One; 2013; 8(8):e72692. PubMed ID: 24023633
[TBL] [Abstract][Full Text] [Related]
13. Interplay of cell adhesion matrix stiffness and cell type for non-viral gene delivery.
Chu C; Kong H
Acta Biomater; 2012 Jul; 8(7):2612-9. PubMed ID: 22510404
[TBL] [Abstract][Full Text] [Related]
14. Identification of MET and SRC activation in melanoma cell lines showing primary resistance to PLX4032.
Vergani E; Vallacchi V; Frigerio S; Deho P; Mondellini P; Perego P; Cassinelli G; Lanzi C; Testi MA; Rivoltini L; Bongarzone I; Rodolfo M
Neoplasia; 2011 Dec; 13(12):1132-42. PubMed ID: 22241959
[TBL] [Abstract][Full Text] [Related]
15. The oncogenic BRAF kinase inhibitor PLX4032/RG7204 does not affect the viability or function of human lymphocytes across a wide range of concentrations.
Comin-Anduix B; Chodon T; Sazegar H; Matsunaga D; Mock S; Jalil J; Escuin-Ordinas H; Chmielowski B; Koya RC; Ribas A
Clin Cancer Res; 2010 Dec; 16(24):6040-8. PubMed ID: 21169256
[TBL] [Abstract][Full Text] [Related]
16. Involvement of superoxide and nitric oxide in BRAF(V600E) inhibitor PLX4032-induced growth inhibition of melanoma cells.
Yu L; Gao LX; Ma XQ; Hu FX; Li CM; Lu Z
Integr Biol (Camb); 2014 Dec; 6(12):1211-7. PubMed ID: 25363644
[TBL] [Abstract][Full Text] [Related]
17. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation.
Nazarian R; Shi H; Wang Q; Kong X; Koya RC; Lee H; Chen Z; Lee MK; Attar N; Sazegar H; Chodon T; Nelson SF; McArthur G; Sosman JA; Ribas A; Lo RS
Nature; 2010 Dec; 468(7326):973-7. PubMed ID: 21107323
[TBL] [Abstract][Full Text] [Related]
18. Myocardial matrix-polyethylene glycol hybrid hydrogels for tissue engineering.
Grover GN; Rao N; Christman KL
Nanotechnology; 2014 Jan; 25(1):014011. PubMed ID: 24334615
[TBL] [Abstract][Full Text] [Related]
19. Collagen hydrogels with controllable combined cues of elasticity and topography to regulate cellular processes.
Oyama TG; Oyama K; Kimura A; Yoshida F; Ishida R; Yamazaki M; Miyoshi H; Taguchi M
Biomed Mater; 2021 Jun; 16(4):. PubMed ID: 34030146
[TBL] [Abstract][Full Text] [Related]
20. Deconstructing the role of the ECM microenvironment on drug efficacy targeting MAPK signaling in a pre-clinical platform for cutaneous melanoma.
Blehm BH; Jiang N; Kotobuki Y; Tanner K
Biomaterials; 2015 Jul; 56():129-39. PubMed ID: 25934286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
